Arava Will Stay On The Market: FDA Denies Public Citizen Petition For Withdrawal
This article was originally published in The Pink Sheet Daily
Executive Summary
Aventis says FDA concluded the benefits of the rheumatoid arthritis therapy outweigh the safety risks. Public Citizen cited severe hepatic reactions and a lack of superiority over other therapies in requesting the drug be pulled.
You may also be interested in...
Arava “Authorized” Generic Will Be Distributed By Prasco
Sanofi-Aventis will supply leflunomide to Prasco, which will distribute the rheumatoid arthritis therapy when other Arava generics enter the market.
Arava “Authorized” Generic Will Be Distributed By Prasco
Sanofi-Aventis will supply leflunomide to Prasco, which will distribute the rheumatoid arthritis therapy when other Arava generics enter the market.
Arava Label Strengthened Following Reports Of Interstitial Lung Disease
Sanofi-Aventis adds stronger warnings for the rheumatoid arthritis drug following post-marketing reports of interstitial lung disease in Japan. Patients should notify their physician and may need to discontinue therapy if pulmonary symptoms develop. Updated labeling also includes geriatric use information.